Fungal cell wall agents and bacterial lipopolysaccharide in organic dust as possible risk factors for pulmonary sarcoidosis by unknown
RESEARCH Open Access
Fungal cell wall agents and bacterial
lipopolysaccharide in organic dust as
possible risk factors for pulmonary
sarcoidosis
Sanja Stopinšek1, Alojz Ihan1, Barbara Salobir2, Marjeta Terčelj2 and Saša Simčič1*
Abstract
Background: Composition of organic dust is very complex, involving particles of microbial, animal and plant origin.
Several environmental exposure studies associate microbial cell wall agents in organic dust with various respiratory
symptoms and diseases. The aim of the present study was to investigate the in vitro effects of the co-exposure of
fungal cell wall agents (FCWAs) and bacterial lipopolysaccharide (LPS) on inflammatory immune responses of
peripheral blood mononuclear cells (PBMCs) from patients with pulmonary sarcoidosis.
Methods: PBMCs from 22 patients with pulmonary sarcoidosis and 20 healthy subjects were isolated and
stimulated in vitro with FCWAs (soluble and particulate (1→ 3)-β-D-glucan, zymosan and chitosan) and/or LPS.
Subsequently, cytokines were measured by ELISA and the mRNA expression of dectin-1, toll-like receptor 2 (TLR2),
TLR4 and mannose receptor (MR) was analysed by real-time RT-PCR.
Results: Patients with sarcoidosis had a significantly higher secretion of inflammatory cytokines tumour necrosis
factor-alpha (TNF-α), interleukin-6 (IL-6), IL-10 and IL-12 (1.7-fold, 2.0-fold, 2.2-fold, and 2.8-fold, respectively; all
p < 0.05) after in vitro co-stimulation of PBMCs with FCWAs and LPS. We showed that PBMCs from patients with
sarcoidosis had a higher baseline mRNA expression of dectin-1, TLR2, TLR4 and MR (6-fold, 11-fold, 18-fold, and 4-fold,
respectively). Furthermore, we found a reduced expression of dectin-1, TLR2 and TLR4 after stimulation with FCWAs
and/or LPS, although the reduction was significantly weaker in patients than in healthy subjects.
Conclusions: In conclusion, co-stimulation with FCWAs and LPS of PBMC from patients with sarcoidosis caused a
weaker reduction of dectin-1, TLR2, TLR4 receptors expression, which could increase the sensitivity of PBMCs, leading
to excessive inflammatory cytokine responses and result in the development or progression of pulmonary sarcoidosis.
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Background
Several environmental exposure studies at workplaces or
at homes associate microbial cell wall agents in organic
dust with various respiratory symptoms and diseases,
although, the immunopathological events involved in
these diseases are very complex and not well under-
stood. We hypothesized that exposure to fungal cell wall
agents (FCWAs) and bacterial lipopolysaccharide (LPS)
in organic dust may represent a risk factor for pulmon-
ary sarcoidosis development or progression.
Sarcoidosis is a chronic granulomatous disease that
most commonly affects the mediastinal lymph nodes
and lungs [1]. Despite intensive research, the aetiology
of sarcoidosis remains unknown. Terčelj et al. proposed
a hypothesis that microbial cell wall agents, particularly
agents from moulds, even in the absence of clinical
infections can cause a late hypersensitivity reaction
leading to granulomas [2]. In support of this hypothesis,
several epidemiological studies describe the association
between sarcoidosis and living in a damp and mouldy
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environment [3–8]. Furthermore, in clinical studies in
which sarcoidosis was treated with antifungals, greater
clinical improvement was reported compared with
corticosteroid treatment [9, 10].
Composition of organic dust is very complex, involv-
ing particles of microbial, animal and plant origin. In
mice models organic dust exposures induced the devel-
opment of lymphoid aggregates, peribronchiolar or vas-
cular inflammation, comprised of T and B lymphocytes
and macrophages with associated neutrophil recruitment
[11]. It has been shown that exposure to high levels of
fungi and their components present in organic dust rep-
resents a risk factor for developing various respiratory
symptoms and diseases, such as asthma, hypersensitivity
pneumonitis, sick building syndrome and organic dust
toxic syndrome [12–14]. Furthermore, bioaerosols with
fungi are known to be associated with granulomatous
diseases [4, 7, 15].
Bacterial LPS is one of the prime constituent in
organic dust. Inhalation studies showed that LPS can
cause cough, dyspnoea, nose and throat irritation, mild
fever, flu-like symptoms, acute air flow obstruction,
airway inflammation or asthma [16]. Furthermore,
adverse effects from LPS may also be increased by other
dampness-associated agents [17].
In our previous study we focused on the in vitro and
in vivo effects of FCWAs in sarcoidosis. The induced in
vitro secretion of cytokines from human peripheral
blood mononuclear cells (PBMCs) was higher from sub-
jects with sarcoidosis than from controls. A significant
relationship was observed between disease severity, mea-
sured as chest X-ray scores indicating granuloma infil-
tration, and the particulate (1→ 3)-β-D-glucan-induced
secretion of cytokines [18–20]. The aim of the present
study was to investigate the in vitro effects of the co-
exposure of FCWAs and LPS on inflammatory immune
responses of PBMCs from patients with sarcoidosis. We
evaluated the FCWAs influence on the in vitro cellular
cytokine response to an inflammatory challenge with
LPS in sarcoidosis and on the mRNA expression of the
main pattern-recognition receptors (PRRs) for recogniz-
ing FCWAs and LPS, dectin-1, toll-like receptor 2
(TLR2), TLR4 and mannose receptor (MR).
Methods
Subjects
The study group consisted of 22 patients newly diag-
nosed with pulmonary sarcoidosis stage II and III
according to the established criteria by the American
Thoracic Society (ATS), European Respiratory Society
(ERS) and World Association of Sarcoidosis and Other
Granulomatous Disorders (WASOG) [21], recruited at
the Department for Respiratory and Allergic Diseases,
University Medical Centre Ljubljana, Slovenia in the
period from September 2008 to January 2012. Patient
characteristics are shown in Table 1. The exclusion
criteria were pulmonary sarcoidosis stage I and IV, CD4/
CD8 ratio in the bronchoalveolar lavage (BAL) less than
4, smoking and receiving any immunosuppressive
therapy.
The control group consisted of 20 healthy blood-
donor volunteers without any respiratory symptoms or
diseases, autoimmune diseases or acute infections. The
study was approved by the National Medical Ethics
Committee of the Republic of Slovenia (number 122/11/
08) and written informed consent was obtained from all
the participants.
Reagents and preparation of FCWAs and LPS
All reagents were commercially obtained from Sigma-
Aldrich Corp. (USA), unless otherwise stated. Reagents
and FCWAs were endotoxin-free and were prepared
exactly as previously described [18]. Briefly, the soluble
and the particulate forms of (1→ 3)-β-D-glucan (BGS
and BGP) consisted of curdlan from Alcaligenes faecalis
var. myxogenes (Wako Pure Chemical Industries, Japan).
BGS was prepared from a suspension of curdlan powder
in 0.3 M sodium hydroxide (NaOH) heated at 80 °C in a
water bath until completely dissolved. The pH of BGS
was neutralized with 0.3 M hydrochloric acid before
being added to cell cultures. Curdlan resuspended in
RPMI-1640 medium supplemented with 25 mM Hepes
buffer (RPMI-1640 medium) represented BGP. Zymosan
A from S. cerevisiae (ZYM) was prepared from a suspen-
sion of ZYM powder, boiled in 0.25 M NaOH and resus-
pended as a 7.5 mg/ml stock solution in RPMI 1640
medium. A low molecular weight (Mw 50–190 kDa)
chitosan from crab shells (75–85 % deacetylated
chitosan, CHT) was prepared as a 2 mg/ml stock
Table 1 Patient and healthy subject characteristics





Age in years mean (range) 44.7 (28–57) 39.9 (25–52)
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solution in 0.2 % acetic acid. The final concentration in
the cell cultures of all FCWAs was 200 μg/ml. LPS from
Escherichia coli (strain 0111:B4) was dissolved as a 1 mg/
ml stock solution in water and further diluted in a cell
culture medium to the final concentration of 10 ng/ml.
Isolation and stimulation of PBMCs
The model that we previously described was used for in
vitro stimulation of PBMCs [18]. Briefly, PBMCs from
patients with sarcoidosis and healthy subjects were
isolated from freshly drawn venous blood with EDTA by
density gradient centrifugation with Ficoll-Paque™ (GE
Healthcare, UK). The cells were cultured in RPMI-1640
medium supplemented with 100 U/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine and 10 %
heat-inactivated human serum (Sigma-Aldrich Corp.,
USA). The 1 × 106 cells (final culture volume of 1.5 ml)
were seeded in 24-well culture plates (Corning Costar,
USA) with medium alone, with LPS (10 ng/ml), with
FCWAs, or with LPS and FCWAs at 37 °C in a humidi-
fied atmosphere of 5 % CO2 in air. The cell-free super-
natants were collected after 4 and 18 h of incubation
and stored at −30 °C before further analysis.
For mRNA expression studies, 1.2 × 105 PBMCs (final
culture volume of 180 μl) were plated in 96-well culture
plates (Greiner Bio-One GmbH, Germany) in medium
alone or with FCWAs (200 μg/ml) in the absence or
presence of LPS (10 ng/ml) at 37 °C in a humidified
atmosphere of 5 % CO2 in air for 4 h.
Real-time reverse transcription polymerase chain reaction
(RT-PCR)
The mRNA expression studies were performed as previ-
ously described [18]. Briefly, the total cellular RNA was ex-
tracted on an ABI Prism 6100 Nucleic Acid PrepStation
(Applied Biosystems, Foster City, USA) according to the
manufacturer’s instructions. RNA was eluted in 150 μl of
elution solution and stored at −80 °C until required. Ten
microliters of total RNA was reverse transcribed in a 27 μl
reaction mixture with a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems) according to the
manufacturer’s instructions on an ABI GeneAmp PCR
System. Real-time PCR was performed on an ABI
StepOnePlus Realtime PCR instrument using a
TaqMan® Universal PCR Master Mix with predeveloped
TaqMan Gene Expression Assay primers and probes
(Dectin-1 Hs00224028_m1, TLR2 Hs00610101_m1, TLR4
Hs01060206_m1 and MR Hs00267207_m1), according to
the manufacturer’s instructions (Applied Biosystems). The
internal endogenous control used was 18S rRNA. Quanti-
fication was performed with the comparative 2−ΔΔCt
method [22]. The amount of target gene was normalized
to the internal control gene (18S rRNA) and the relative
expression of target genes in cultured PBMCs was
calculated in relation to the mean values of target gene ex-
pression in healthy subjects after 4 h of incubation in
medium alone.
Cytokine measurements
Cytokine concentrations in cell culture supernatants
were measured by commercially available enzyme-linked
immunosorbent assay (ELISA) kits. Tumour necrosis
factor-alpha (TNF-α) (Milenia Biotec, Germany) was
measured after 4 h of incubation. The concentrations of
interleukin-6 (IL-6), IL-10 and IL-12 (Thermo Scientific,
USA) were measured after 18 h of incubation.
Statistical analysis
All statistical analyses were performed using PSAW/
SPSS for Windows version 18 (SPSS Inc., IBM Com-
pany, USA). Results are presented as the mean +/−
standard error of the mean (SEM). Statistically signifi-
cant differences in cytokine concentration or in mRNA
gene expression between the two groups of subjects
were estimated by the nonparametric Mann-Whitney
test. P values less than 0.05 were considered statistically
significant.
Results
In vitro inflammatory cytokine response to FCWAs and
LPS by PBMCs from patients with sarcoidosis
After co-stimulation of PBMCs with FCWAs and LPS,
the production of TNF-α, IL-6, IL-10 and IL-12 was
significantly higher in patients with sarcoidosis, com-
pared to healthy subjects (1.7-fold, 2.0-fold, 2.2-fold, and
2.8-fold, respectively; all p < 0.05) (Fig. 1). Fold changes
are mean values calculated from all four combinations of
FCWAs and LPS. Patients with sarcoidosis thus elicited
higher levels of in vitro inflammatory cytokine response
of PBMCs after co-stimulation with FCWAs and LPS
than healthy subjects.
PBMCs mRNA expression of dectin-1, TLR2, TLR4, and MR
at baseline and after in vitro stimulation with FCWAs and/
or LPS in patients with sarcoidosis
As shown in Fig. 2, baseline dectin-1, TLR2, TLR4 and
MR mRNA expression in PBMCs was higher in patients
with sarcoidosis than in healthy subjects (6-fold, 11-fold,
18-fold, and 4-fold, respectively).
When PBMCs were stimulated with FCWAs and/or
LPS the mRNA expression of dectin-1, TLR2 and TLR4
was lower than at baseline in both groups of subjects.
However, the expression was significantly higher in
patients compared to healthy, indicating a weaker reduc-
tion of PRRs expression upon FCWAs and/or LPS
stimulation in patients with sarcoidosis. Similar results
were obtained after 4 and 18 h of incubation (data not
shown).
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Discussion
This study was designed to investigate the in vitro effects
of the co-exposure of FCWAs and LPS on inflammatory
immune responses of PBMCs from patients with
sarcoidosis. The main results obtained from this study
show that patients with sarcoidosis had a significantly
higher secretion of inflammatory cytokines TNF-α, IL-6,
IL-10 and IL-12 after in vitro co-stimulation of PBMCs
with FCWAs and LPS. We showed that PBMCs from
patients with sarcoidosis had a higher mRNA expression
of dectin-1, TLR2, TLR4 and MR at baseline. Further-
more, we found a reduced expression of dectin-1, TLR2
and TLR4 after stimulation with FCWAs and/or LPS,
although the reduction was significantly weaker in
patients than in healthy subjects.
The organic dust we breathe contains particles of
animal, plant and microbial origin, of which the most
important in relation to respiratory diseases are fungal
(1→ 3)-β-D-glucan and bacterial LPS [14]. We demon-
strated previously that after in vitro stimulation of
PBMCs with FCWAs alone, the secretion of TNF-α, IL-
6, IL-10 and IL-12 was higher in patients with
sarcoidosis compared to healthy subjects [20]. These
cytokines have all been implicated in the immunopatho-
genesis of sarcoidosis [1, 23–25]. Since FCWAs and LPS
might have a synergistic effect on the immune responses
of patients with sarcoidosis, we investigated in the
present study the in vitro synthesis of inflammatory
cytokines in PBMCs after co-stimulation with FCWAs
and LPS. Our results showed that patients with sarcoid-
osis, compared to healthy subjects, had a significantly
higher secretion of inflammatory cytokines TNF-α, IL-6,
IL-10 and IL-12, after co-stimulation of PBMCs with
FCWAs and LPS. However, it should be noted that pa-
tients with sarcoidosis included in this study had an on-
going inflammatory disease, which may have influenced
the immune responses in our in vitro experiments.
In addition to having a strong impact on in vitro hu-
man PBMCs inflammatory cytokine responses, FCWAs
have been shown to have various biological and immu-
nopharmacological properties (reviewed in [26, 27]). A
causal role in the development of respiratory symptoms
and diseases associated with fungal exposure has been





































































































Fig. 1 Cytokine responses of PBMCs after in vitro stimulation with FCWAs and/or LPS. PBMCs (1 × 106 cells/ml) were isolated from venous blood
of patients with sarcoidosis (n = 22) and healthy subjects (n = 20) and incubated with medium alone or stimulated with FCWAs (200 μg/ml) and/
or LPS (10 ng/ml). Supernatant TNF-α (pg/ml) (a) after 4 h of incubation, IL-6 (pg/ml) (b), IL-10 (pg/ml) (c) and IL-12 (pg/ml) (d) after
18 h of incubation were measured by ELISA. The results are presented as the mean cytokine concentration in culture supernatants with SEM. *p < 0.05,
**p < 0.001: significantly different cytokine production between patients with sarcoidosis and healthy subjects. LPS: lipopolysaccharide, BGS: soluble
(1→ 3)-β D-glucan, BGP: particulate (1→ 3)-β-D-glucan, ZYM: zymosan, and CHT: chitosan
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been shown to trigger rheumatoid arthritis in genetically
susceptible mice, suggesting that fungal infection may
evoke autoimmune conditions in genetically susceptible
individuals [30]. Chitin has also been implicated in
asthma and allergy [31]. Furthermore, it has been dem-
onstrated that fungi [4, 32, 33] or (1→ 3)-β-D-glucan it-
self [34, 35] can trigger granuloma formation. In view of
all this, we speculated that FCWAs in combination with
LPS may evoke an exaggerated inflammatory reaction in
genetically susceptible individuals and lead to sarcoid
granuloma formation or progression of the disease.
Recent genetic studies suggest that PRRs might be
involved in the pathogenesis of sarcoidosis [36–43]. The
central PRRs involved in the recognition of fungi are C-
type lectin receptors, such as dectin-1 and MR; TLRs,
such as TLR-2, −4 and −9; and the galectin family pro-
teins [44]. The key receptor involved in bacterial LPS
recognition is TLR4 [45]. All biological activities of
(1→ 3)-β-D-glucan are mediated by dectin-1, which also
collaborates with TLR2 and TLR4. On the other hand, the
immunomodulating effects of chitin and its derivatives are
mediated by pathways that involve TLR2, dectin-1 and
MR [46]. In our previous study, we examined the in vitro
effects of FCWAs alone or in combination with LPS on
PRRs mRNA expression in healthy subjects [18]. Since
these receptors are suspected of being involved in the
pathogenesis of sarcoidosis, we examined the effects of
FCWAs and/or LPS on the mRNA expression of these
receptors in PBMCs from patients with sarcoidosis.
Our results demonstrated that PBMCs from patients
with sarcoidosis had a higher in vitro baseline mRNA
expression of dectin-1, TLR2, TLR4 and MR than healthy
subjects. The results are in accordance with Wiken et al.
[37], who found that TLR2 and TLR4 expression on
peripheral blood monocytes at baseline was significantly
higher in patients with sarcoidosis than in healthy sub-
jects, as measured by flow cytometry. We found a reduced
expression of dectin-1, TLR2 and TLR4 after stimulation
with FCWAs and/or LPS, although the reduction was
significantly weaker in patients than in healthy subjects.
That may indicate a defect in down-regulation of PRRs in












































































































































Fig. 2 Dectin-1, TLR2, TLR4 and MR mRNA expression in PBMCs. PBMCs (1.2 × 105) from sarcoidosis patients (n = 5) and healthy subjects (n = 5)
were incubated in vitro with medium alone or stimulated with FCWAs (200 μg/ml) and/or LPS (10 ng/ml). After 4 h of incubation the mRNA
levels of dectin-1 (a), TLR2 (b), TLR4 (c) and MR (d) were analysed by real-time RT-PCR. The results were normalized against the mRNA expression
of 18S rRNA. Data are means ± SEM. *p < 0.05, **p < 0.01: significant difference of mRNA gene expression between sarcoidosis patients and healthy
subjects. LPS: lipopolysaccharide, BGS: soluble (1→ 3)-β-D-glucan, BGP: particulate (1→ 3)-β-D-glucan, ZYM: zymosan, and CHT: chitosan
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Conclusions
In conclusion, microbial cell wall agents are airborne and
poorly degradable antigens to which we are constantly
exposed. Our study demonstrated that co-stimulation with
FCWAs and LPS of PBMC from patients with sarcoidosis
caused a weaker reduction of dectin-1, TLR2, TLR4 recep-
tors expression, which could increase the sensitivity of
PBMCs, leading to excessive inflammatory cytokine
responses and result in the development or progression of
pulmonary sarcoidosis.
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